Scalp Psoriasis Management in Patients with Hepatic or Renal Disease

Pathophysiology and Treatment Considerations

The American Academy of Dermatology states that scalp psoriasis results from immune-mediated keratinocyte hyperproliferation and impaired differentiation, with vitamin D analogues working by binding vitamin D receptors to inhibit keratinocyte proliferation and enhance differentiation 1
The disease manifests as inflammatory plaques characterized by erythema 2

The American Academy of Dermatology recommends combination calcipotriene/betamethasone dipropionate as the most effective first-line treatment for mild-to-moderate scalp psoriasis, achieving clear or almost clear status in 40.9% of patients at 8 weeks versus 24.2% with vehicle 1
Calcipotriene foam or calcipotriene plus betamethasone dipropionate gel for 4-12 weeks is safe and effective for scalp psoriasis 1
In pediatric patients ≥12 years, calcipotriol/betamethasone suspension once daily for up to 8 weeks is recommended 3

Methotrexate is absolutely contraindicated in patients with significant hepatic damage, as it causes hepatotoxicity, fibrosis, and cirrhosis with prolonged use 5, 6, 7
Pretreatment assessment must include liver function tests and clinical liver examination 2
Periodic liver biopsies are recommended for psoriatic patients under long-term treatment, as fibrosis and cirrhosis may occur without preceding symptoms or abnormal liver function tests 2

Cyclosporine is absolutely contraindicated in patients with abnormal renal function, as it causes nephrotoxicity with increasing risk at higher doses and longer duration 5, 6
Methotrexate elimination is reduced in patients with impaired renal function, requiring especially careful monitoring for toxicity, dose reduction, or discontinuation 5, 6, 7
Vitamin D analogues should be used with caution in patients with renal disease or disorders of calcium metabolism 3

For patients with hepatic disease, avoid methotrexate entirely if significant hepatic damage exists, and consider cyclosporine or retinoids with close liver function monitoring 8, 2
For patients with renal disease, cyclosporine is absolutely contraindicated, and methotrexate requires dose reduction and intensive monitoring 2, 8

Systemic corticosteroids are contraindicated in psoriasis as they can precipitate erythrodermic psoriasis, generalized pustular psoriasis, or very unstable psoriasis upon withdrawal 4, 5, 6, 9, 2
Methotrexate can cause fetal death and congenital anomalies; contraception required 8
Cyclosporine increases risk of malignancies, particularly skin cancers and lymphoproliferative disorders 9